Viyash Scientific Limited
NSE: VIYASHMarket Closed • NSE
Day range
52 week range
Viyash Scientific Limited closed at INR226.00 (+0.03%) on volume 1.09x its 20-day average, trading 24.16% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved +35.6% QoQ
2021-09-08
DIVIDEND Announced
Dividend - Rs 0.50 Per Share
2019-08-21
DIVIDEND Announced
Annual General Meeting/Dividend - Rs 0.20 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.16x
High Cash Flow Conversion: CFO/PAT averaged 3.33x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 55.3x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 10 Sept 2021 | Dividend | ₹0.50 / share | — | 08 Sept 2021 |
| — | Dividend | ₹0.20 / share | — | 21 Aug 2019 |
| 09 Apr 2018 | Scheme Of Arrangement | Scheme Of Arrangement | — | 06 Apr 2018 |
| 21 Nov 2017 | Dividend | ₹0.20 / share | — | 20 Nov 2017 |
| — | Annual General Meeting | Annual General Meeting | — | 15 Sept 2016 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
IndiaHealthcare
Is Viyash Scientific Limited Shariah compliant?
Viyash Scientific Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (4.91%) complies with AAOIFI threshold (≤ 33%).
What is Viyash Scientific Limited's current valuation relative to peers?
Viyash Scientific Limited trades at a P/E of 55.3x compared to the sector median of 37x, and a Price-to-Book of 3.4x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.16x. Interest coverage is 6.1x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.